Avadel to Present at H.C. Wainwright 22nd Annual Global Investment Conference


DUBLIN, Ireland, Sept. 11, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL) a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate, today announced that its executive team will be presenting at the H.C. Wainwright 22nd Annual Global Investment Conference taking place September 14 – 16, 2020.

Read more here:
Avadel to Present at H.C. Wainwright 22nd Annual Global Investment Conference

Related Posts